Hsbc Holdings PLC Invests $1.42 Million in Collegium Pharmaceutical, Inc. $COLL

Hsbc Holdings PLC bought a new position in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) in the second quarter, HoldingsChannel reports. The firm bought 39,609 shares of the specialty pharmaceutical company’s stock, valued at approximately $1,424,000.

Several other institutional investors also recently bought and sold shares of COLL. Group One Trading LLC bought a new stake in Collegium Pharmaceutical in the 4th quarter valued at $28,000. Caitong International Asset Management Co. Ltd lifted its stake in Collegium Pharmaceutical by 205.3% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 635 shares of the specialty pharmaceutical company’s stock worth $29,000 after purchasing an additional 427 shares in the last quarter. Kemnay Advisory Services Inc. bought a new position in shares of Collegium Pharmaceutical during the 4th quarter valued at about $61,000. PNC Financial Services Group Inc. boosted its holdings in shares of Collegium Pharmaceutical by 42.2% during the 1st quarter. PNC Financial Services Group Inc. now owns 1,408 shares of the specialty pharmaceutical company’s stock valued at $47,000 after purchasing an additional 418 shares during the last quarter. Finally, EverSource Wealth Advisors LLC grew its position in shares of Collegium Pharmaceutical by 744.9% during the second quarter. EverSource Wealth Advisors LLC now owns 2,484 shares of the specialty pharmaceutical company’s stock valued at $73,000 after purchasing an additional 2,190 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on COLL. Wall Street Zen cut Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Needham & Company LLC dropped their price target on Collegium Pharmaceutical from $56.00 to $46.00 and set a “buy” rating for the company in a research note on Thursday, August 6th. Truist Financial upgraded Collegium Pharmaceutical to a “strong-buy” rating in a report on Monday, June 15th. Weiss Ratings downgraded Collegium Pharmaceutical from a “hold (c)” rating to a “hold (c-)” rating in a research note on Tuesday, August 11th. Finally, Zacks Research cut Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 28th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $51.00.

Collegium Pharmaceutical Stock Performance

Shares of NASDAQ:COLL opened at $24.61 on Tuesday. The firm has a fifty day simple moving average of $32.78 and a two-hundred day simple moving average of $34.82. Collegium Pharmaceutical, Inc. has a 52 week low of $24.47 and a 52 week high of $50.79. The company has a quick ratio of 0.84, a current ratio of 1.03 and a debt-to-equity ratio of 3.32. The stock has a market capitalization of $801.30 million, a P/E ratio of 19.85 and a beta of 0.73.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its earnings results on Thursday, August 6th. The specialty pharmaceutical company reported $1.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.72 by $0.20. Collegium Pharmaceutical had a net margin of 5.93% and a return on equity of 91.43%. The firm had revenue of $199.88 million for the quarter, compared to analysts’ expectations of $199.62 million. During the same period in the prior year, the company earned $1.68 EPS. The business’s revenue was up 6.3% compared to the same quarter last year. On average, analysts expect that Collegium Pharmaceutical, Inc. will post 6.51 earnings per share for the current fiscal year.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.